Trial Profile
Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 1 Trial)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Therapeutic Use
- Acronyms The Endurance 1 Trial
- 01 Feb 2019 Status changed from recruiting to completed.
- 27 Nov 2014 New trial record